https://www.selleckchem.com/pr....oducts/liraglutide.h
No outside funding supported the writing of this commentary. Hsu reports research support from Vedanta Biosciences and consulting fees from EBSCO, outside the submitted work.BACKGROUND Cardiovascular disease (CVD) remains the most prevalent cause of morbidity and mortality in patients with type 2 diabetes (T2D) and is a primary driver for health care costs associated with diabetes management. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant r
Beğen
Yorum Yap
Paylaş
